Although erlotinib has approvals in other indications (i.e., maintenance and unselected NSCLC after failure of one chemotherapy), in reality, said Dr. Padda, its most important indication is for the treatment of EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.